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Abstract
Linear ubiquitin chains are important regulators of cellular signaling pathways that control innate
immunity and inflammation through NF-κB activation and protection against TNFα-induced
apoptosis1-5. They are synthesized by HOIP, which belongs to the RBR (RING-between-RING)
family of E3 ligases and is the catalytic component of LUBAC (linear ubiquitin chain assembly
complex), a multi-subunit E3 ligase6. RBR family members act as RING/HECT hybrids,
employing RING1 to recognize ubiquitin-loaded E2 while a conserved cysteine in RING2
subsequently forms a thioester intermediate with the transferred or “donor” ubiquitin7. Here we
report the crystal structure of the catalytic core of HOIP in its apo form and in complex with
ubiquitin. The C-terminal portion of HOIP adopts a novel fold that, together with a zinc finger,
forms an ubiquitin-binding platform which orients the acceptor ubiquitin and positions its α-amino
group for nucleophilic attack on the E3~ubiquitin thioester. The carboxy-terminal tail of a second
ubiquitin molecule is located in close proximity to the catalytic cysteine providing a unique
snapshot of the ubiquitin transfer complex containing both donor and acceptor ubiquitin. These
interactions are required for activation of the NF-kB pathway in vivo and explain the determinants
of linear ubiquitin chain specificity by LUBAC.
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Protein modification with ubiquitin is a key mechanism for the regulation of numerous
cellular functions8. The transfer of ubiquitin onto a substrate is catalyzed by E3 ligases,
which can be classified into RING, HECT and RBR families9-13. Two LUBAC subunits
contain RBR domains. However, HOIP constitutes the catalytic center and its RBR domain-
containing C-terminal region (HOIPRBR-C) is sufficient to synthesise linear ubiquitin chains,
regardless of E2 (Fig. 1a)6,14,15. Although the RING1 domain of RBRs is assumed to be the
primary binding site for E2s, we show that a HOIP construct containing only the catalytic
cysteine-carrying RING2 plus a C-terminal extension (HOIPCBR-C) still forms linear
ubiquitin chains, at a ~7-fold slower rate than HOIPRBR-C (Fig. 1b and Extended Data Fig.
1)7,15. Hence HOIPCBR-C constitutes the minimal catalytic core. We have determined the
crystal structure of this catalytic core in its apo form at 2.4 Å and in complex with ubiquitin
at 1.6 Å resolution (Extended Data Table 1). HOIPCBR-C consists of 7 α-helices and 4 zinc-
binding modules and its overall topology appears distinct from other structures (Figs. 1c-e
and Extended Data Fig. 2). The helical region forms an elongated structural unit that acts as
a platform, the “helical base”, to support the zinc-binding modules. The RING2 region of
RBRs has recently been shown to adopt the IBR domain fold in auto-inhibited Parkin and
HHARI16-21. This fold is preserved in the structure of active HOIPCBR-C (Fig. 1c-e and
Extended Data Fig. 3) and based on this structural and high sequence conservation we
suggest it be renamed CBR (for “catalytic IBR”). Remarkably, the second zinc-binding site
of the CBR of HOIPCBR-C has a zinc finger (ZF1) inserted between the second and third
Zn2+-coordinating residues. A fourth zinc-binding site is located between helices α3 and α4
(ZF2) and anchors the β-hairpin that is positioned close to the CBR.
In the HOIPCBR-C/ubiquitin complex, ubiquitin makes contacts with residues from the
helical base and ZF1 (Fig. 2 and Extended Data Fig.4). No major conformational changes
occur upon complex formation, although some disordered regions of apo HOIPCBR-C
become ordered (Extended Data Fig. 2d). The ubiquitin bound by the helical base and ZF1
constitutes the acceptor ubiquitin: its α-amino-group of M1 is located 3.5 Å away from the
thioester-forming C885, poised for nucleophilic attack (Fig. 2). Strikingly, the C-terminal
G76 of ubiquitin from a symmetry-related molecule is oriented such that its carboxylate
points into the active site of HOIPCBR-C sufficiently close to C885 to promote thioester
formation. Thus, the molecular arrangement within the crystal lattice mimics the
biologically relevant ubiquitin transfer complex with the donor and acceptor ubiquitin in an
orientation consistent with linear chain synthesis (Fig. 2 and Extended Data Fig.4).
Unexpectedly, we found additional electron density in the active site, which we interpret as
a zinc ion. However, mass spectrometry, combined with structural and biochemical analysis
show that ubiquitin chain synthesis is not a zinc-dependent process (Extended Data Figs. 2b
and 5).
HOIPCBR-C employs residues from helices α2 and α6 in the helical base to contact T14,
E16, D32 and K33 of the acceptor ubiquitin, while ZF1 rests against helix α1 and the
preceding loop (Fig. 3a and Extended Data Fig. 6a) ensuring that the N-terminal amino
group is positioned closest to the active site and thus specifying linear chain synthesis.
Notably, the side chain of M1 points away from the active site indicating that its selection is
stereochemically driven. To analyze the role of individual residues in ligase activity we used
a combination of steady state and single-turnover assays (Fig. 3c, d and Extended Data Fig.
6). Contributions from the helical base are crucial for ubiquitin chain synthesis, especially
R935 and D936, but their mutation does not impede thioester formation (Extended Data Fig.
6c). In ubiquitin the most severe effect was seen upon K33 mutation, while E16A and D32A
showed reduced activity. No point mutation could be identified at the ZF1-ubiquitin
interface that reduced chain synthesis, however, ZF1 deletion results in an almost complete
loss of activity (Fig. 3c). This impairment is not caused by protein misfolding since
ubiquitin-thioester formation is unaffected (Extended Data Fig. 6c). Instead, ZF1 deletion
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abolishes transfer of the donor onto the acceptor ubiquitin. These data suggest that the
helical base constitutes the primary binding site for the acceptor ubiquitin which is further
supported by ZF1.
HOIPCBR-C residues that contact the acceptor ubiquitin are located in a region termed the
“linear ubiquitin chain determining region” (LDD, residues 910-1,082)15. Our structure now
shows that this is not an independent ubiquitin binding-module, but together with the CBR
forms a super-domain which contacts donor and acceptor ubiquitin to create a platform that
promotes linear chain synthesis.
Contacts between HOIPCBR-C and the donor ubiquitin primarily involve the C-terminal tail
of ubiquitin which is guided towards the active site through a channel created by the N-
terminal anti-parallel β-strands of the CBR and a β-hairpin formed by βF and βE (Fig. 2 and
3b). These structural elements restrict tail mobility ensuring that the carboxylate of G76 is
located next to the catalytic cysteine. Contacts between Q974 and D983 in the β-hairpin and
R72 and R74 from ubiquitin are crucial for donor ubiquitin binding (Fig. 3b-d and Extended
Data Fig. 6). Interestingly the β-hairpin is largely disordered in the apo structure suggesting
that, together with the CBR, it could act as a flexible clamp locking the donor ubiquitin into
place. Ubiquitin is further sandwiched by the N-terminal β-sheets of the CBR that form a
hydrophobic pocket which accommodates L73 and contacts L71. Mutation of either results
in severe loss of activity (Figs. 3c). Most of the hydrophobic residues contacting L71 and
L73 are conserved in CBRs, indicating that this mode of donor ubiquitin presentation to the
substrate may be a general property of RBRs (Extended Data Fig.3).
To confirm that the mechanism of linear ubiquitin chain synthesis identified in HOIPCBR-C
is maintained in LUBAC, we carried out in vitro ubiquitination assays with the
heterotrimeric complex. While the activity of LUBAC is lower than of isolated HOIPRBR-C,
possibly due to regulatory roles of ubiquitin binding domains present in all 3 subunits, there
is a strong correlation with the trends seen in ubiquitination assays using different ubiquitin
mutants, indicating that domains outside HOIPRBR-C do not affect chain linkage specificity
(Extended Data Fig. 7). To validate our conclusions in a physiological context, we carried
out in vivo NF-kB activation and p65 nuclear translocation assays employing HOIP mutants
shown to affect interaction with the donor (D983A) and acceptor (R935A, D936A)
ubiquitin. Consonant with our structural and biochemical data these mutants reduced NF-κB
signalling and p65 nuclear translocation upon overexpression (Figs. 3e, f) without impairing
complex formation between LUBAC subunits (Extended Data Fig. 7).
Ubiquitin chain synthesis involves the nucleophilic attack of an amino group from a lysine
or the N-terminus of ubiquitin onto an ubiquitin-thioester formed by the E2 or HECT-type
E3s. The reaction requires a general base to deprotonate the nucleophile and a mechanism to
stabilize the transition state22-24. In the HOIPCBR-C/ubiquitin complex, H887 of HOIPCBR-C
forms a hydrogen bond with M1 of ubiquitin suggesting it could activate the incoming α-
amino group or stabilize the transition state. To test its contribution to catalysis, we
measured the activity of H887A which was reduced over 1000-fold at 15°C. This is due to
lack of transfer onto the acceptor ubiquitin rather than impairment of thioester formation
(Figs. 3d and 4a). Thus H887 is not required for transthiolation from E2 to E3. To further
characterize its function, we tested if activity could be rescued at increased pH, which would
aid deprotonation of the nucleophile. Indeed, ubiquitin transfer assays with H887A showed
that activity could be restored at pH 9.0, although this required higher temperature and
substrate concentrations (Fig. 4b). Accordingly, enzyme activity is lost below pH 6.0, the
approximate pKa of an imidazole sidechain (Extended Data Fig. 8). Taken together, these
observations support a model for ubiquitin transfer in which H887 acts as a general base to
activate the nucleophile (Fig. 4c). This mechanism is maintained in vivo as indicated by the
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reduction of NF-κB activation and p65 translocation by the H887A mutant (Figs. 3e, f).
Notably, a histidine in this position is conserved in a number of RBRs and has recently been
shown to be important for activity in Parkin and HHARI16,17,20, suggesting that the
mechanism of nucleophile activation may be conserved.
The HOIPCBR-C/ubiquitin complex structure presented here provides the first insights into
how an E3 ligase directs the synthesis of specific ubiquitin chains: a non-covalent ubiquitin
binding site orients the acceptor so that only the α-amino group of M1 is presented to the
active site, similar to the mechanism used by linkage specific E2s 24-26 (Extended Data Fig.
9). M1 is part of a β-sheet and less flexible than the ε-amino group of lysine, potentially
explaining why HOIP has evolved a single structural unit that integrates the CBR domain
with the donor and acceptor ubiquitin binding regions. Comparison of CBR structures from
active HOIP with auto-inhibited Parkin and HHARI suggests that the overall mechanism of
donor ubiquitin presentation is conserved in the RBR family16-21. Further studies are now
required to reveal the mechanism that promotes formation of the active ligase complex and
explain how chain linkage specificity is achieved in other RBR ligases.
METHODS
Cloning, expression and protein purification
Cloning, expression and purification of Ube1, UbcH5A (UBE2D1), HOIPRBR-C and
mutants thereof, HOIP (residues 300-1072), HOIL-1L, SHARPIN and His6-M1C-ubiquitin
have been described14. HOIPCBR-C was expressed and purified using the same procedure as
for HOIPRBR-C. Point mutations were generated using the QuikChange site-directed
mutagenesis kit (Stratagene). The ZF1 of HOIP (residues 906-923) was deleted in
HOIPRBR-C and replaced with the sequence PG using Overlap Extension-PCR27. Untagged
ubiquitin and mutants were prepared according to Pickart and Raasi28. Seleno-methionine
(SeMet)-substituted proteins were produced by standard procedures. Ubiquitin used for
crystallization was purchased from Sigma and further purified by gel filtration. All plasmids
were verified by DNA sequencing. Protein molecular mass was verified by electrospray
ionization mass-spectrometry. The fold of all proteins was analyzed by circular dichroism
spectroscopy.
Ubiquitination assays
Ubiquitination assays were performed using 1 μM E1, 5 μM UbcH5A, 5 μM HOIP (or 5μM
each: HOIP residues 300-1072, HOIL-1L and SHARPIN) and 200 μM ubiquitin14.
Reactions were incubated at 30°C for 1 h and samples taken at 0, 5, 15, 30, 60 min
(HOIPRBR-C) or 0.5, 1, 2, 4 hrs (HOIPCBR-C). Reactions were stopped by addition of SDS
sample buffer containing 40 mM N-Ethylmaleimide (NEM). For LUBAC assays an
additional precipitation step using 50 mM NaAc, pH 4.0/60°C was introduced. Samples
were analyzed by SDS-PAGE and visualized using Coomassie Brilliant blue.
Thioester formation and ubiquitin transfer assays
Labelling of His6-Cys-ubiquitin with Cy5-Maleimide mono-Reactive Dye (GE Healthcare)
and transfer assays were carried out as described with minor modifications14. 1 μM Cy5-
ubiquitin was mixed with 2 μM E1 and 1 mM ATP. After 5 min 10 μM UbcH5A was added
and after further 5 min 20 μM HOIPRBR-C. To monitor ubiquitin transfer, 10 μM Ub-His6
was added. Samples were taken before each addition and analysed by SDS-PAGE in the
absence and presence of DTT.
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UbcH5A was charged with Cy5-labeled linear di-ubiquitin and purified by gel filtration. 0.3
μM or 3.0 μM (for pH-dependent assays) of E2~thioester was mixed with 0.3μM or 3.0 μM
Cy3-labeled linear di-ubiquitin. After addition of 3.0 μM of HOIPRBR-C or HOIPCBR-C,
tetra-ubiquitin chain synthesis was observed by fluorescence resonance energy transfer
(FRET) between Cy3 and Cy5 using excitation and emission wavelengths of 540 nm and
670 nm, respectively. Samples were incubated at 15° C in 50 mM HEPES pH 7.4, 150 mM
NaCl, or at 25°C for pH-dependent assays using phosphate (pH 6-8) and CHES (pH
8.5-10.0) buffers. Data were analyzed by single exponential curve fitting. Data for
constructs with very low activity were analyzed by linear regression and a rate constant was
calculated by dividing the obtained slope by the amplitude taken from the HOIPRBR-C WT
measurement. All measurements were carried out in duplicate or triplicate and mean values
are given.
Luciferase and p65 translocation assays
HeLa cells were transfected with pCMV-FLAG-HOIP (WT, H887A, R935A, D936A,
D983A), pcDNA5-HA-SHARPIN, pNF-κB-Luc (Stratagene) and β-GAL plasmids using
Genejuice. After 36 hrs of transfection, lysates were prepared and subjected to luciferase
assays following the manufacturer’s protocol (Roche). Internal control was measured by β-
Gal activity using its substrate (Roche). Three independent experiments were performed
using triplicate samples in each experiment. For translocation assays HeLa cells were fixed
and stained for p65 (SantaCruz, sc-372) and HA-SHARPIN (Covance, MMS-101P). The
total number of cells showing nuclear staining of p65 was counted and normalized to the
total number of cells expressing HA-SHARPIN to determine the percentage of translocation.
Three independent experiments were performed using triplicate samples in each experiment.
Results were analyzed by ANOVA1 followed by Tukey post-tests and are presented as
average plus s.e.m. ** p<0.01; *** p<0.001 compared to WT HOIP.
Co-immunoprecipitation assays
HeLa cells were transfected with pCMV-FLAG-HOIP, pcDNA5-HA-SHARPIN and
pcDNA5-HA-HOIL-1L plasmids. After 36h FLAG-HOIP immunoprecipitation was
performed using anti-FLAG M2 affinity gel (Sigma). The samples were subsequently
probed for FLAG-HOIP, HA-SHARPIN and HA-HOIL-1L.
Crystallisation of apo HOIPCBR-C and the ubiquitin complex
Crystallisation trials with HOIPCBR-C and its SeMet-derivative were set-up at 9.5 mg/ml
using an Oryx crystallisation robot. Initial hits were optimised by sitting drop vapour
diffusion at 18 °C with a reservoir solution containing 100 mM Tris pH 8.5, 800 mM LiCl
and 20 % PEG 12000. Crystals were flash-frozen in the reservoir solution containing 30 %
glycerol. HOIPCBR-C (0.6 mM) and ubiquitin were mixed at 1:2 and 1:3 molar ratios. Initial
crystals were obtained in the Morpheus screen and optimised in hanging-drops with
reservoir solution containing 0.1 M carboxylic acids, buffer system 1 (0.1 M) pH 6.5, 30%
P550 MME _P20K. Crystals were flash-frozen in the reservoir solution. Crystals of mutant
HOIPCBR-C H899A with ubiquitin were grown under the same conditions as the wild-type
protein.
Data collection and structure determination
Crystals of HOIPCBR-C diffracted to 2.44 Å. A data set was collected on beamline IO3
(λ=0.9798 Å) at the Diamond Light Source (Oxford, UK) and processed using XDS29. The
structure was solved by single wavelength anomalous dispersion phasing using the SeMet-
derivative of HOIPCBR-C. Heavy atom search, density modification, and initial model
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building was performed using Phenix AutoSol30. Diffraction data for crystals of HOIPCBR-C
(WT) and HOIPCBR-C (H889A) in complex with ubiquitin were collected at beamline IO4
(λ=1.282 Å), and IO4-1 (λ=0.9163 Å), respectively. Data were reduced using Xia2 from the
CCP4 suite and the structure of the complex was determined by molecular replacement in
Phaser31 using the apo structure and ubiquitin (1UBQ.pdb) as search models. All models
were iteratively improved by manual building in Coot32 and refined using REFMAC533 and
Phenix30. The stereochemistry of the final models was 05analyzed with Procheck. The
model of apo HOIPCBR-C has 94.8% of residues in favored regions, 4.2% in allowed regions
and 1% outliers. The final models of WT HOIPCBR-C/ubiquitin and HOIPCBR-C H889A/
ubiquitin have 97.6% and 95.5% of residues in the favored regions of Ramachandran plot,
respectively. Structural figures were prepared in Pymol.
Mass spectrometry
For zinc content analysis by native mass spectrometry, purified proteins were dialysed at 4
°C against 20 mM ammonium acetate pH 7.4. Molecular mass was determined by
electrospray ionisation (ESI) on a microTOFQ electrospray mass spectrometer (Bruker
Daltonics, Coventry, UK). Protein was infused into the mass spectrometer at 3 μl/min using
an electrospray voltage of 4.5 kV. Inductively coupled plasma mass spectrometry (ICP-MS)
was used to determine the concentration of Ca and Zn (as 44Ca and 66Zn) in the protein
samples using an Agilent 7700x instrument in Helium (He) collision mode.
Analytical ultracentrifugation
Sedimentation velocity experiments were performed in a Beckman XL-I analytical
ultracentrifuge. Samples were dialyzed against the buffer blank, 20 mM Tris-HCl, 150 mM
NaCl, 0.5mM TCEP, pH 7.5. Centrifugation was performed at 50,000 rpm and 293 K in an
An50-Ti rotor at 125 μM sample concentrations. Data were analyzed in terms of the size
distribution function C(S) using the program SEDFIT34.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Structure of the catalytic core of HOIP
a, Composition of LUBAC. Boxed: the crystallized catalytic core HOIPCBR-C, biochemical
assays employed HOIPRBR-C. Below, schematic of new elements identified: CBR, ZF1, ZF2
and helical base. b, Single turnover assays showing that lack of RING1 reduces activity 6.8-
fold (HOIPCBR-C, 0.050 min−1 versus HOIPRBR-C, 0.341 min−1). c-e, Ribbon representation
of HOIPCBR-C with the helical base in grey, CBR in purple, ZF1 in cyan and ZF2 and β-
hairpin in green, zinc ions as spheres, coordinating residues as ball and sticks and the
catalytic cysteine in yellow. The structure represents HOIPCBR-C from the ubiquitin
complex and includes regions disordered in the apo form.
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Fig. 2. The HOIPCBR-C/ubiquitin transfer complex containing donor and acceptor ubiquitin
a, Ribbon representation of HOIPCBR-C in complex with the acceptor (orange) and donor
(yellow) ubiquitin. HOIPCBR-C is shown in the same orientation as in Fig. 1e. The positions
of C885, donor G76 and acceptor M1 are indicated. Insert, contacts made by HOIPCBR-C
with donor and acceptor ubiquitin. The arrow shows the proximity between G76 of the
donor and Sγ of C885. b, The HOIPCBR-C/ubiquitin complex with HOIPCBR-C shown in a
surface representation to emphasize the spatial relationship between the 3 molecules.
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Fig. 3. Contacts between HOIPCBR-C and ubiquitin required for ubiquitin transfer
a, Close-up of the HOIPCBR-C/acceptor ubiquitin interface focusing on the helical base and
ZF1. b, Details of the HOIPCBR-C/donor ubiquitin (yellow) interface. Positions of C885 and
acceptor ubiquitin M1 are indicated. c, Steady-state ubiquitination assays. Mutants that
target the acceptor interface are boxed in orange, those with donor in yellow. d, Single-
turnover assays to determine the rate of tetraubiquitin formation. e, Luciferase assays
showing that the NF-κB pathway is not efficiently activated by HOIP mutants H887A,
R935A, D936A and D983A compared to WT. f, p65 translocations assay showing impaired
p65 nuclear translocation upon expression of HOIP ligase-deficient mutants. Three
independent experiments were performed using triplicate samples. Results were analyzed by
ANOVA1 followed by Tukey post-tests. ** p<0.01; *** p<0.001 compared to wild-type
HOIP.
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Fig. 4. HOIP H887 acts as the general base to activate the nucleophile
a, HOIPRBR-C H887A and H889A (which shows WT activity) mutants can form a thioester
(lanes 1 and 2 of each mutant), indicating that neither residue is involved in transthiolation
from E2 to E3. However, H887A has lost the ability to transfer to a substrate to form
diubiquitin. An orange square indicates the presence of acceptor ubiquitin. b, Single-
turnover assays of the pH-dependence of tetraubiquitin formation showing that the H887A
mutant regains activity at higher pH at 25°C. c, Proposed mechanism for ubiquitin transfer
by HOIP.
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